NEW YORK, March 19 (Bernama-BUSINESS WIRE) -- Today Dataiku, the leading Enterprise AI and machine learning platform, announced the release of Dataiku 7, bringing deeper integration for technical data professionals to work on machine learning project development and row-level explainability for white-box AI. Additional feature highlights with this latest release include Kubernetes-powered web apps to expand on the capabilities introduced in Dataiku 6 and a machine learning-assisted data labeling plugin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005008/en/ “Collaboration has been at the core of Dataiku since our founding in 2013, and with Dataiku 7, we’re continuing to add features that deepen our philosophy to effectively democratize AI in the enterprise,” said Dataiku CEO, Florian Douetteau. “With this launch, Dataiku 7 is our second consecutive product release that expands features for explainable AI, a critical component for organizations across industries to succeed and understand the impact of their AI model outcomes.” Organizations worldwide are committed to enterprise AI efforts from the top down, but struggle to democratize projects from the bottom up to give more individuals access to actionable data insights. Dataiku 7 brings more people to the table via collaboration and empowers individuals with explainable AI for businesses to use data for day-to-day decisions and build impactful AI projects. With the launch of Dataiku 7, new features include: Support for Advanced Statistical Analysis: Statisticians can now use Dataiku to perform advanced statistical analysis in the familiar worksheet-and-cards format while collaborating with the wider data or analytics team. In the past, advanced statisticians were relegated to siloed tools with no visibility for non-statisticians, creating bottlenecks in governance and AI project deployment. http://mrem.bernama.com/viewsm.php?idm=36984
0 Comments
KUALA LUMPUR, March 18 -- CSOP Asset Management Limited (CSOP) has announced the listing of CSOP CSI 500 ETF (stock ticker: HKD counter 3005.HK/ RMB counter 83005.HK) on the Hong Kong Stock Exchange. According to a statement, the listing enables global investors to access the China A-shares benchmark reflecting the performance of small-mid capitalisation stocks. With listing price at approximate HKD 16 per unit, trading lot of 200 and management fee of 0.99 per cent, CSOP CSI 500 ETF will start to trade on March 19 as the only ETF tracking CSI 500 Index (CSI 500) in China offshore market. (HKD 1 = RM0.56) Upon inception, CSOP CSI 500 ETF received US$100 million initial investment. Same as the FTSE China A50 Index (China A50 Index) and CSI 300 Index (CSI 300), the CSI 500 is a China A-shares benchmark. (US$1 = RM4.37) Different from the China A50 Index and CSI 300 tracking performance of large capitalisation stocks, CSI 500 aims to reflect the overall performance of small-mid capitalisation stocks. Compared with CSI 300, CSI 500 exhibits more characteristics of diversification and growth. The largest sector in CSI 500 is IT with 22 per cent weighting, less than the 33 per cent weighting of financials in CSI 300. As a leading China A-shares ETF leading provider, CSOP brought CSOP FTSE China A50 ETF (HKD counter 2822.HK/ RMB counter 82822.HK) to global investor in 2012. After eight years, CSOP introduced the CSOP CSI 500 ETF to market, offering another China A-shares investment tool with broader coverage of China’s economy. -- BERNAMA KUALA LUMPUR, March 16 -- Algernon Pharmaceuticals Inc (Algernon), a clinical stage pharmaceutical development company has filed its pre-IND (Investigational New Drug) meeting request with the US FDA.
This initiates formal communications with the US FDA regarding development of its re-purposed drug NP-120 (Ifenprodil) for the treatment and prevention of acute lung injury (ALI) and acute respiratory distress syndrome associated with COVID-19 (coronavirus) infection. According to a statement, the request for a pre-IND meeting was accompanied by the complete pre-IND briefing document. In the application, the company has requested direction regarding the use of Algernon’s planned new propriety injectable and slow release formulation as well as the use of its currently available Ifenprodil drug supply, for a US clinical trial on an emergency use basis. This filing also includes clarification of the expanded access pathway, also known as the ‘compassionate use’ pathway. The decision to file with the US FDA was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40 per cent. Asian H5N1 is the most lethal form of influenza known to date with over 50 per cent mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. -- BERNAMA SINGAPORE, March 16 (Bernama-BUSINESS WIRE) — AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “a-” of Tower Insurance Limited (TIL) (New Zealand). Concurrently, AM Best has affirmed the Long-Term ICR of “bbb-” of TIL’s ultimate parent, Tower Limited (TL) (New Zealand). The outlook of these Credit Ratings (ratings) remains stable.
The ratings reflect TIL’s balance sheet strength, which AM Best categorizes as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. TIL’s balance sheet strength assessment is underpinned by its risk-adjusted capitalization, as measured by Best’s Capital Adequacy Ratio (BCAR), which is expected to remain at least at a very strong level over the medium term. AM Best also views TIL as having robust financial flexibility as a result of its ownership by TL, a listed company with a track record of accessing capital markets. In September 2019, following a rights issue at TL, a capital injection of NZD 45 million was provided to TIL. This was to support the purchase of Youi NZ Pty Limited’s (Youi NZ) insurance portfolio and strengthen TIL’s capital position in light of a change to its license conditions imposed by the Reserve Bank of New Zealand, with effect from Oct. 31, 2019. The modified license conditions require TIL to remove Earthquake Commission (EQC) receivables emanating from the Canterbury earthquakes in 2010 and 2011 from its solvency calculations, as a result of the increased likelihood of litigation and associated delay in receiving funds. While AM Best considers TIL’s ongoing exposure to the Canterbury earthquakes as a partially offsetting balance sheet factor, reflecting the potential for future adverse reserve development and lower-than-expected EQC recoverables, the capital raising actions in 2019 have provided an improved buffer against these risks in TIL’s capital adequacy. http://mrem.bernama.com/viewsm.php?idm=36963 New findings reveal consumer appetite for advanced messaging functionality, but operators must place privacy, security and person-to-person functionality at the core of new messaging services
BRIDGEWATER, N.J., March 13 (Bernama-GLOBE NEWSWIRE) -- The United States is a market primed for operator-sponsored, brand- targeted advanced messaging based on Rich Communications Services (RCS), according to focus group conversations conducted by Synchronoss (NASDAQ: SNCR). After bringing together dozens of U.S. consumers of all ages to discuss their mobile messaging habits, Synchronoss is able to show the value of RCS to operators and brands to increase subscriber engagement and create new revenue. RCS is an easy-to-use, feature-rich, interactive cross-operator advanced messaging platform that will be available on all mobile devices. This evolution of operator-led SMS messaging not only incorporates advanced multimedia capabilities into text messages but also gives users the ability to accomplish everything they currently do across multiple apps from a single messaging platform and with a single contact list for friends, family and services. RCS also serves as a powerful, private-by-design direct marketing ecosystem that operators can offer to brands. Brands will be able to leverage a new secure, permission-based, personalized communications channel and take advantage of SMS’s higher open, response and click-through rates. At the same time, operators will gain an opportunity to grow their revenue outside of traditional lines of business and further solidify their own reputations as protectors of subscriber privacy. Synchronoss, a global leader and innovator of cloud, messaging, digital and IoT products and the provider behind the RCS-based +Message service launched by three major Japanese operators in May 2018, asked focus group participants about their current messaging behavior and introduced them to RCS capabilities. The resulting discussions demonstrated a clear demand for operator-sponsored RCS, with convenience and operator trust at the heart of participants’ excitement for this new form of mobile communication. http://mrem.bernama.com/viewsm.php?idm=36946 KUALA LUMPUR, March 13 -- The Sabin Vaccine Institute (Sabin) has received a three-year grant valued at US$10.4 million via a National Philanthropic Trust grant to strengthen vaccine acceptance. (US$1 = RM4.29)
According to a statement, the funding will launch Sabin’s new Vaccine Acceptance and Demand initiative and support several programme areas. The programme areas are educating media and healthcare professionals on vaccines and immunisation, supporting community-level social and behavioural research to understand vaccine acceptance and hesitancy, and enhancing understanding of social media influence on vaccination decisions. The initiative is led by Sabin Global Immunization President, Dr Bruce Gellin. “Vaccine hesitancy is creating a global health risk that must be addressed. Misinformation and disinformation about vaccines cost lives daily in communities around the world, as witnessed during the ongoing global measles resurgence,” said Dr Gellin. “Through Sabin’s role at the intersection of immunisation programmes, policy and research, we will partner with local researchers, national immunisation programmes and other global health organisations to build evidence and provide the resources, connections and information stakeholders need to reverse this dangerous trend.” In 2019, the World Health Organization identified vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – as one of the top 10 threats to global health. More details at https://www.sabin.org/ -- BERNAMA KUALA LUMPUR, March 12 -- Ultrasound is widely used for conducting physical examinations, and plans are underway to expand its application to treat Parkinson's disease, dementia and diabetes. The National Tsing Hua University’s research team has successfully improved the motor symptoms of Parkinson’s disease in mice by injecting cellular proteins that are highly sensitive to ultrasound waves into the deep brain region and afterwards using ultrasound to activate the neuron cells. The research was led by Associate Professor Yu-Chun Lin of the Institute of Molecular Medicine and Professor Chih-kuang Yeh of the Department of Biomedical Engineering and Environmental Sciences. Their innovative research has been published in the January issue of Nano Letters, and their non-invasive treatment has already been patented in Taiwan and the United States, according to a statement. “Parkinson’s disease and Alzheimer’s disease are caused by the degeneration and death of the cells in the brain. But once the cells with prestin gene fragments have been transplanted into the target area, ultrasound can be applied to awaken atrophied cells so that they can begin to form new neural connections,” said Yeh. The team has produced a video showing how a mouse with Parkinson's disease stops short while crossing a wooden bridge and how the same mouse, following cell transplantation and ultrasound treatment, crosses the bridge easily. It has also been found that the treatment results in a significant increase in dopamine levels in the brain, demonstrating its effectiveness in the treatment of Parkinson's disease. The same procedure can also be used to treat diabetes by stimulating insulin-producing cells. -- BERNAMA KUALA LUMPUR, March 12 -- The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools has announced the addition of Nova School of Business & Economics (Nova SBE) into its membership.
Nova SBE is one of Portugal’s top business schools. The addition brings GMAC’s total membership to 229 institutions, according to a statement. GMAC member schools go through an invitation-only process governed by the organisation’s board of directors. Nominees then participate in a comprehensive application process that addresses the sustained commitments to supporting GMAC’s mission: providing the tools and information necessary for schools and talent to discover and evaluate each other. Nova SBE considers itself a community of world citizens. Sharing GMAC’s vision of diversity, the institution strives to stay at the forefront of innovation while preparing executives and entrepreneurs of tomorrow to contribute to a more open, sustainable and inclusive world. Financial Times has ranked the school 22nd for its International Master's in Management worldwide; 21st for its International Master’s in Finance worldwide; and, among the top 30 Business Schools in Europe. To be considered for membership in GMAC, schools complete an application process and must maintain a selective admissions process and actively support GMAC’s mission and use GMAT exam or other GMAC assessments as part of admissions and enrollment processes. More details at www.gmac.com. -- BERNAMA SYMPHONY HEALTH PARTNERS WITH DATAVANT FOR THE INDUSTRY’S DEEPEST VIEW OF THE PATIENT JOURNEY13/3/2020 RALEIGH, N.C., March 12 (Bernama-GLOBE NEWSWIRE) — PRA Health Sciences (NASDAQ: PRAH) announced today a partnership between Symphony Health and Datavant that expands the breadth of data available for integration and allows life sciences companies to get the deepest and most holistic view of the patient journey in the commercial market. Symphony Health’s proprietary Synoma® de-identification engine enables integration of complementary data sets from across the health ecosystem using a unique token. By working closely with Datavant, Symphony Health gives its customers the flexibility to connect data integrated via Synoma to the hundreds of unique data sets available through Datavant. By leveraging best-in-class de-identification and integration with Symphony Health’s proprietary Synoma engine, customers will be able to connect, expand and analyze all relevant data types – electronic health records, medical and pharmacy claims, diagnostic lab datasets, demographics, and information from patient wearables and sensors collected during clinical trials. Leveraging these integrated data sets, customers can then build bespoke, fit-for-purpose data assets, custom data strategies and develop unique insights for their business with support from PRA and Symphony data experts. http://mrem.bernama.com/viewsm.php?idm=36934 JAKARTA, March 12 (Bernama) -- “Betul, Betul, Betul!”, a jargon that is very well known within Indonesian entertainment audiences. It’s none other than the cutie twins, Upin & Ipin. Along with Pekan Raya Jakarta 2020, the twins will greet their Indonesian fans with the newest format, a musical theatre titled “Upin & Ipin PIN PIN POM!”. The show will be held on May 30th-31st and June 1st 2020.
Upin & Ipin became the most favored animation by Indonesian kids. The real story contains great learning for kids, making Indonesian parents keen to serve this show as an entertainment for their kids. Les’ Copaque Production, the production house of Upin & Ipin has won more than 50 national and international awards. “Upin & Ipin: The Lone Gibbon Kris” even became the first Malaysian movie to be shortlisted in the Animated Feature category for The Academy Awards 2020. This performance brings the twins’ story where they find a magic scarlet stone in their village. This scarlet stone belongs to the wicked Nenek Kebayan. The journey of Upin & Ipin starts to save their village by defeating Nenek Kebayan with their magic power. This is the first time Upin & Ipin hold their musical in Indonesia. Indonesia being the world premiere of this brand new musical, will visit various parts of the country such as Bandung and Surabaya. Upin, Ipin and friends will be presented LIVE to dance and sing during this musical, promises a great fun and entertainment for everyone. Biz Trends Media Pte Ltd, Singapore-based entertainment company, licensed to stage this musical, partnering with several parties such as BookMyShow as the exclusive ticketing partner and Jakarta Fair Kemayoran 2020 to bring this musical to Indonesia. Ticket price starts from Rp 350,000 and can be purchased starting from March 13th 2020 only at id.bookmyshow.com or BookMyShow Indonesia mobile app. SOURCE: Les’ Copaque Production Sdn. Bhd. FOR MORE INFORMATION, PLEASE CONTACT: Indonesia Name: Martina Solya Marketing Manager Tel: 0878-9768-3698 Email: [email protected] Malaysia Name: Mohd Zarin Abdul Karim Tel: 012- 239 9327 Email: [email protected] http://mrem.bernama.com/viewsm.php?idm=36939 |
Archives
April 2023
Categories |